Lipocine (NASDAQ:LPCN) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a research report report published on Sunday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Trading Down 0.9 %

LPCN stock opened at $3.28 on Friday. The firm has a 50-day moving average price of $3.68 and a 200-day moving average price of $4.52. Lipocine has a 12 month low of $2.91 and a 12 month high of $11.79. The stock has a market capitalization of $17.55 million, a P/E ratio of -4.32 and a beta of 1.42.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Lipocine stock. Geode Capital Management LLC increased its position in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 57,464 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,248 shares during the period. Geode Capital Management LLC owned about 1.07% of Lipocine worth $280,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.